Podocalyxin Is Required for Maintaining Blood–Brain Barrier Function During Acute Inflammation
Podocalyxin is required for maintaining blood–brain barrier function during acute inflammation Jessica Caita, Michael R. Hughesa,1, Matthew R. Zeglinskib,c,d, Allen W. Chane,f,g,h,i, Sabrina Osterhofa, R. Wilder Scotta,j, Diana Canals Hernaeza, Alissa Caita, A. Wayne Voglj,k, Pascal Bernatchezd,l, T. Michael Underhilla,j, David J. Granvilleb,c,d, Timothy H. Murphye,f,g, Calvin D. Roskelleyj,k, and Kelly M. McNagnya,1 aBiomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; bICORD Centre, University of British Columbia, Vancouver, BC, Canada V5Z 1M9; cDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada V6T 2B5; dCentre for Heart and Lung Innovation, St Paul’s Hospital, Vancouver, BC, Canada V6Z 1Y6; eDepartment of Psychiatry, University of British Columbia, Vancouver, BC, Canada V6T 2A1; fKinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z4; gDjavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; hNeuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada T6G 2R3; iNeurochemical Research Unit, Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada T6G 2R3; jDepartment of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z4; kLife Sciences Institute, University of British Columbia, Vancouver, BC, Canada V6T 1Z4; and lDepartment of Anaesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada V6T 1Z3 Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved January 15, 2019 (received for review September 6, 2018) Podocalyxin (Podxl) is broadly expressed on the luminal face of and plasma factors to effect repair.
[Show full text]